Elks M L, Manganiello V C
Endocrinology. 1984 Oct;115(4):1262-8. doi: 10.1210/endo-115-4-1262.
3T3-L1 adipocytes contain both soluble and particulate cAMP phosphodiesterases which can be distinguished by several criteria. Particulate phosphodiesterase activity of 3T3-L1 adipocytes, but not undifferentiated fibroblasts, was selectively increased by incubation of cells with insulin or lipolytic hormones. Particulate cAMP phosphodiesterase activity from 3T3-L1 adipocytes was very sensitive to inhibition by cilostamide in an apparently competitive fashion. Particulate activity from undifferentiated 3T3-L1 fibroblasts or supernatant activity from either type of cell was much less sensitive to cilostamide. On the other hand, supernatant cAMP phosphodiesterase activity from both undifferentiated fibroblasts and 3T3-L1 adipocytes was very sensitive to inhibition by Ro-20-1724 in an apparently competitive fashion. Ro-20-1724 was not an effective inhibitor of particulate activity from either type of cell. In fractions from 3T3-L1 adipocytes, isobutylmethylxanthine (IBMX) effectively inhibited both supernatant and particulate cAMP phosphodiesterase activities. In addition, however, IBMX was relatively more specific in inhibiting supernatant calmodulin-activated cGMP phosphodiesterase activity than supernatant calmodulin-independent or particulate cGMP phosphodiesterase activities. In intact 3T3-L1 adipocytes, cilostamide enhanced lipolysis in the absence or presence of isoproterenol and had no effect on cAMP content in the presence of low concentrations of isoproterenol. Ro-20-1724 increased lipolysis to a lesser extent than cilostamide and did not enhance isoproterenol-stimulated lipolysis, but did increase isoproterenol-stimulated accumulation of cAMP to a greater extent than cilostamide. Like cilostamide, Ro-20-1724 did not enhance accumulation of cAMP in the absence of isoproterenol. IBMX enhanced lipolysis and cAMP accumulation with or without isoproterenol. Taken together, these results support the idea that although particulate and soluble low Km phosphodiesterases influence cAMP content, the particulate enzyme may be more important in the metabolism of cAMP involved in the regulation of lipolysis. Since combinations of Ro-20-1724 and cilostamide were not as effective as IBMX in increasing cAMP content, perhaps the calmodulin-dependent phosphodiesterase, which is selectively inhibited by IBMX, is also involved in the regulation of total cell cAMP content.
3T3-L1脂肪细胞含有可溶性和颗粒性的环磷酸腺苷磷酸二酯酶,这两种酶可通过多种标准加以区分。用胰岛素或脂解激素孵育细胞后,3T3-L1脂肪细胞(而非未分化的成纤维细胞)的颗粒性磷酸二酯酶活性会选择性增加。3T3-L1脂肪细胞的颗粒性环磷酸腺苷磷酸二酯酶活性对西洛他唑的抑制作用非常敏感,表现为明显的竞争性抑制。未分化的3T3-L1成纤维细胞的颗粒性活性或两种细胞的上清液活性对西洛他唑的敏感性要低得多。另一方面,未分化的成纤维细胞和3T3-L1脂肪细胞的上清液环磷酸腺苷磷酸二酯酶活性对Ro-20-1724的抑制作用非常敏感,表现为明显的竞争性抑制。Ro-20-1724对两种细胞的颗粒性活性均不是有效的抑制剂。在3T3-L1脂肪细胞的组分中,异丁基甲基黄嘌呤(IBMX)可有效抑制上清液和颗粒性环磷酸腺苷磷酸二酯酶的活性。然而,除此之外,与上清液中不依赖钙调蛋白的或颗粒性的环鸟苷酸磷酸二酯酶活性相比,IBMX在抑制上清液中钙调蛋白激活的环鸟苷酸磷酸二酯酶活性方面相对更具特异性。在完整的3T3-L1脂肪细胞中,无论有无异丙肾上腺素,西洛他唑均可增强脂解作用,且在低浓度异丙肾上腺素存在时对环磷酸腺苷含量无影响。Ro-20-1724增强脂解作用的程度小于西洛他唑,且不增强异丙肾上腺素刺激的脂解作用,但在增强异丙肾上腺素刺激的环磷酸腺苷积累方面比西洛他唑更有效。与西洛他唑一样,在无异丙肾上腺素时Ro-20-1724也不增强环磷酸腺苷的积累。无论有无异丙肾上腺素,IBMX均可增强脂解作用和环磷酸腺苷的积累。综上所述,这些结果支持以下观点:尽管颗粒性和可溶性低Km磷酸二酯酶会影响环磷酸腺苷含量,但颗粒性酶在参与脂解调节的环磷酸腺苷代谢中可能更为重要。由于Ro-20-1724和西洛他唑的组合在增加环磷酸腺苷含量方面不如IBMX有效,或许被IBMX选择性抑制的钙调蛋白依赖性磷酸二酯酶也参与了细胞内环磷酸腺苷总量的调节。